SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmion -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (10)9/14/2005 2:08:21 PM
From: tuck  Respond to of 22
 
5q deletion in about 25% of patients, according to CELG. Meanwhile, here's a fairly recent looking analyst report on PHRM, courtesy of YMB poster:

finance.messages.yahoo.com

and next post. EMEA decision on Vidaza and earnings look to be the next near term catalysts, then an inlicensing next year.

Cheers, Tuck



To: tuck who wrote (10)9/14/2005 3:48:12 PM
From: tuck  Read Replies (1) | Respond to of 22
 
>>My impression is that R is more efficacious, but not as safe.<<

80% of Revlimid patients had Grade 3 or 4 adverse events:

Message 21703221

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News